Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Development of a clinical metagenomics workflow for wound swab samples

PROVIDER: PRJNA1147578 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30219800_1.fastq.gz	Fastqsanger.gz
	SRR30219801_1.fastq.gz	Fastqsanger.gz
	SRR30219802_1.fastq.gz	Fastqsanger.gz
	SRR30219803_1.fastq.gz	Fastqsanger.gz
	SRR30219804_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 38

Similar Datasets

Clinical metagenomics analysis of wound swab samples.

Project description:Clinical metagenomics analysis of wound swab samples.

| PRJEB78614 | ENA

Project description:Clinical metagenomics analysis of wound swab samples

| PRJNA1146314 | ENA

A Metagenomics Analysis of Pandemic 2009 H1N1 Infection in Patients in North America

Project description:The Virochip microarray (version 4.0) was used to detect viruses in patients from North America with unexplained influenza-like illness at the onset of the 2009 H1N1 pandemic. We used metagenomics-based technologies (the Virochip microarray) and deep sequencing to analyze nasal swab samples from individuals with 2009 H1N1 infection. This Series includes the Virochip microarray data only.

2010-11-01 | E-GEOD-24034 | biostudies-arrayexpress

A SISCAPA-based approach for detection of SARS-CoV-2 viral antigens from clinical samples.

Project description:SARS-CoV-2 has created a global disease burden infecting >100 million humans in just over a year. In this study, we adopted a SISCAPA-based enrichment approach using anti-peptide antibodies generated against peptides from the nucleocapsid protein of SARS-CoV-2. We developed a targeted workflow in which nasopharyngeal samples were digested followed by enrichment of viral peptides using the anti-peptide antibodies and targeted parallel reaction monitoring (PRM) analysis using a high-resolution mass spectrometer. This workflow was applied to 41 RT-PCR-confirmed clinical nasopharyngeal swab samples and 30 negative samples. The SISCAPA-based platform described in the current study can serve as one of the alternative methods for SARS-CoV-2 viral detection.

2022-06-03 | PXD026273 | Pride

A SISCAPA-based approach for detection of SARS-CoV-2 viral antigens from clinical samples.

2022-02-16 | PXD028505 | Pride

A mass spectrometry-based targeted assay for detection of SARS-CoV-2 antigen from clinical specimens

Project description:The COVID-19 pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has overwhelmed health systems worldwide and highlighted limitations of diagnostic testing. Several types of diagnostic tests including RT-PCR-based assays and antigen detection by lateral flow assays, each with their own strengths and weaknesses, have been developed and deployed in a short time. Here, we describe an immunoaffinity purification approach followed a by high resolution mass spectrometry-based targeted qualitative assay capable of detecting SARS-CoV-2 viral antigen from nasopharyngeal swab samples. Based on our discovery experiments using purified virus, recombinant viral protein and nasopharyngeal swab samples from COVID-19 positive patients, nucleocapsid protein was selected as a target antigen. We then developed an automated antibody capture-based workflow coupled to targeted high-field asymmetric waveform ion mobility spectrometry (FAIMS) - parallel reaction monitoring (PRM) assay on an Orbitrap Exploris 480 mass spectrometer. An ensemble machine learning-based model for determining COVID-19 positive samples was developed using fragment ion intensities from the PRM data. The optimized targeted assay, which was used to analyze 88 positive and 88 negative nasopharyngeal swab samples for validation, resulted in 98% (95% CI = 0.922-0.997) (86/88) sensitivity and 100% (95% CI = 0.958-1.000) (88/88) specificity using RT-PCR-based molecular testing as the reference method. Our results demonstrate that direct detection of infectious agents from clinical samples by tandem mass spectrometry-based assays have potential to be deployed as diagnostic assays in clinical laboratories, which has hitherto been limited to analysis of pure microbial culture

2020-08-13 | PXD020644 | Pride

Project description:Targeted metagenomics on respiratory pathogens in nasopharyngeal swab samples.

| PRJNA562998 | ENA

Project description:Human clinical samples virus-metagenomics

| PRJNA1110171 | ENA

Project description:Nasal pharyngeal swab metagenomics

| PRJNA613697 | ENA

human metagenome

Project description:Swab samples Metagenome

| PRJNA260809 | ENA